巴雷特食管演变为食管腺癌的研究进展

doi:10.3969/j.issn.2095-378X.2020.02.009

Abstract

Abstract: Barrett esophagus (BE) refers to the replacement of normal lamellar squamous epithelium in the lower esophagus by metaplasia of columnar epithelium. BE is the strongest risk for esophageal adenocarcinoma (EAC). The evolution and progression from BE to EAC has become the research focus of BE. Many key signaling factors and signaling pathways are involved. This paper reviewed the research progress on how BE evolves into EAC.

Key words: Barrett esophagus, Esophageal adenocarcinoma, Pathogenesis, Signaling pathway

CLC Number:

R735.1

YAO Liwen, XU Shuchang. Reseach progress on development of Barrett esophagus to esophageal adenocarcinoma[J]. Surgical Research and New Technique, 2020, 9(2): 100-104.

References

[1] Ross-Innes C S, Becq J, Warren A, et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett’s esophagus and esophageal adenocarcinoma[J].Nat Genet, 2015,47(9):1038-1046.
[2] Weaver J M J, Ross-Innes C S, Shannon N, et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis[J].Nat Genet,2014,46(8):837-843.
[3] Stachler M D, Camarda N D, Deitrick C, et al.Detection of mutations in Barrett’s esophagus before progression to high-grade dysplasia or adenocarcinoma[J].Gastroenterology,2018,155(1):156-167.
[4] Guo X, Tang Y, Zhu W.Distinct esophageal adenocarcinoma molecular subtype has subtype-specific gene expression and mutation patterns[J].BMC Genomics,2018,19(1):769.
[5] Horvath B, Singh P, Xie H, et al.Expression of P53 predicts risk of prevalent and incident advanced neoplasia in patients with Barrett’s esophagus and epithelial changes indefinite for dysplasia[J].Gastroenterol Rep (Oxf),2016,4(4):304-309.
[6] Kastelein F, Biermann K, Steyerberg E W, et al.Aberrant P53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett’s oesophagus[J].Gut,2013,62(12):1676-1683.
[7] Yan H P, Roberts L J, Davies S S, et al.Isolevuglandins as a gauge of lipid peroxidation in human tumors[J].Free Radic Biol Med,2017,106(5):62-68.
[8] Pretto G, Gurski R R, Binato M, et al.Increase of epidermal growth factor receptor expression in progression of GERD,Barrett and adenocarcinoma of esophagus[J].Dig Dis Sci,2013,58(1):115-122.
[9] Kim J, Bowlby R, Mungall A, et al.Integrated genomic characterization of oesophageal carcinoma[J].Nature,2017,541(7636):169-175.
[10] Xiong D D, He R Q, Lan A H, et al. Clinical significances of p27 in digestive tract cancers:a comprehensive analysis on immunohistochemistry staining, published literatures, microarray and RNA-seq data[J].Oncotarget, 2018, 9(15):12284‐12303.
[11] Alves-Fernandes D K, Jasiulionis M G. The role of SIRT1 on DNA damage response and epigenetic alterations in cancer[J].Int J Mol Sci,2019,20(13):3153.
[12] Majka J, Wierdak M, Szlachcic A, et al.Interaction of epidermal growth factor with COX-2 products and peroxisome proliferator-activated receptor-γ system in experimental rat Barrett’s esophagus[J].Am J Physiol Gastrointest Liver Physiol,2020,318(3):G375-G389.
[13] Haque S, Morris J C.Transforming growth factor-β: A therapeutic target for cancer[J].Hum Vaccin Immunother,2017,13(8):1741-1750.
[14] Lee S W, Lien H C, Lin C C, et al.Low expression of transforming growth factor β in the epithelium of Barrett’s esophagus[J].Gastroenterology Res,2018,11(3):189-194.
[15] Wang D H, Tiwari A, Kim M E, et al. Hedgehog signaling regulates FOXA2 in esophageal embryogenesis and Barrett’s metaplasia[J].Clin Invest, 2014, 124(9): 3767‐3780.
[16] Gibson M K, Zaidi A H, Davison J M, et al. Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease[J].Ann Surg,2013,258(1):82‐88.
[17] Götzel K, Chemnitzer O, Maurer L, et al.In-depth characterization of the Wnt-signaling/β-catenin pathway in an in vitro model of Barrett’s sequence[J].BMC Gastroenterol,2019,19(1):38.
[18] Grewal U S, Randhawa M S, Mehta A.Role of mitochondrial markers in improved detection and risk-stratification in Barrett’s esophagus patients[J].Yale J Biol Med,2019,92(3):533-539.
[19] Phelan J J, Mac Carthy F, Feighery R, et al.Differential expression of mitochondrial energy metabolism profiles across the metaplasia-dysplasia-adenocarcinoma disease sequence in Barrett’s oesophagus[J].Cancer Lett,2014,354(1):122-131.
[20] Varghese S, Newton R, Ross-Innes C S, et al. Analysis of dysplasia in patients with Barrett’s esophagus based on expression pattern of 90 genes[J].Gastroenterology,2015,149(6):1511-1518.

Reseach progress on development of Barrett esophagus to esophageal adenocarcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 5

Recommended Articles

Metrics

Comments

[1]	WANG Anfeng, PAN Chen, TONG Xiaowen. Research progress on TLR4/MyD88 signaling pathway in paclitaxel-resistant ovarian carcinoma [J]. Surgical Research and New Technique, 2019, 8(1): 49-53.
[2]	WANG Chaolan, ZHU Tianmin. Exploration of pathogenesis and clinical treatment for sacroiliac joint pain after lumber fusion [J]. Surgical Research and New Technique, 2018, 7(1): 61-64.
[3]	. Bioinformatics applications in the pathogenesis and drug design of Alzheimer's disease [J]. Surgical Research and New Technique, 2016, 5(1): 53-56.
[4]	. Bithionol inhibit proliferation and induce apoptosis in glioma cell U251: a in vitro study [J]. Surgical Research and New Technique, 2015, 4(3): 158-162.
[5]	YU Tao,YU Guang-rong. A potential target for treatment of osteosarcoma:TWEAK/Fn14 signaling pathway [J]. 外科研究与新技术, 2013, 2(1): 62-65.